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Background/aim: A variation in the 3 prime untranslated regions (3′-UTRs) affects the binding of microRNA (miRNA) to the breast
cancer (BC) susceptibility gene 1 (BRCA1) gene, and thus regulate its expression. In this study, the consequences of a variation in the
miRNA-binding site (rs8176318G>T) in the 3′-UTRs of BRCA1 and its association with the risk of BC were investigated.
Materials and methods: The selected variation (rs8176318G>T) was genotyped in BC patients (n = 300) and healthy controls (n = 300)
using allele-specific polymerase chain reaction (PCR) [tetra-primer amplification refractory mutation system-PCR (T-ARMS-PCR)].
The results of the T-ARMS-PCR were further confirmed by Sanger sequencing through a random selection of 10% previously analyzed
samples by T-ARMS-PCR. Association of this variation with BC was tested by calculating the odds ratio (OR) (at 95% CI) and χ2-value
using 4 different genetic models (codominant, dominant, recessive, and additive models).
Results: Using Fisher’s exact test, a significant association between variant rs8176318 (G>T) and BC was found in codominant [χ2-value
= 15.68, df: 2 P < 0.0004], dominant [OR = 1.557 (1.082–2.241), P <0.0213], recessive [OR = 0.474 (0.3204–0.7017), P = 0.0002] and
additive models [OR = 1.609 (1.282–2.018), P < 0.0001].
Conclusion: It was therefore concluded that there is a significant association between rs8176318 and BC risk in a case-control study in
a Pakistani population. Furthermore, an association study using a large sample size is required to further verify these findings.
Key words: Case-control study, single nucleotide polymorphism, untranslated regions, miRNAs

1. Introduction
Breast cancer (BC) is estimated to be the second leading
cause of cancer related death in women worldwide [1].
There are several environmental and genetic factors
contributing to BC. Among genetic factors, a number of
protein coding and noncoding genes contribute to the
etiology of BC. BC susceptibility gene 1 (BRCA 1) is one
of the main protein-coding genes related to the causes of
BC. Mutations in BRCA1 account for about 40%–45% of
BCs [2]. Defects in BRCA1 affect the cell cycle at various
points, destabilizing the DNA and triggering DNA
damage response, hence increasing the formation of
tumors [3,4]. BRCA1 is specifically involved in repairing
breaks in double-stranded DNA, transcription, and
recombination. The frequency and types of mutations in
BRCA1 vary among different populations worldwide. The
3 prime untranslated regions (3′-UTRs) of BRCA1 play
a pivotal role in the stability, localization, and transport

of mRNA, hence affecting its expression [5,6]. Single
nucleotide polymorphisms (SNPs) in the 3′-UTRs affect
the expression of genes, thus influencing the risk of cancer
development. It has been reported that SNPs in the 3′UTRs of BRCA1 disturb the binding sites of microRNA
(miRNA). Therefore, it can be used as a biomarker for BC
[7]. A previous study reported that the homozygous (TT)/
heterozygous (TG) variant is linked with increased risk of
BC [8].
MiRNAs are small noncoding RNA molecules that
control gene expression by regulating their corresponding
mRNA. They act by binding to their target through
miRNA:mRNA complementary base pairing at the
untranslated regions of the genes. The capability of
miRNAs binding to their target mRNA in the 3′-UTR is
crucial for the proper expression of proteins. However, the
binding capacity can be adversely affected by mutations/
SNPs in the sites to which miRNA binds in the gene [9].
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These observations lead to the assumption that
unidentified variations in the miRNA binding sites at the
3′-UTR of the BRCA1 could provide an important insight
into the etiology of BC risk factors.
Several techniques are used for the detection of
mutations in the genome. However, tetra-primer
amplification refractory mutation system-polymerase
chain reaction (T-ARMS PCR) is a flexible, fast, and
inexpensive SNP discovery strategy when compared to
other genotyping tools [10]. It includes a single PCR and
subsequent gel electrophoresis [11]. It utilizes 4 primers, 2
inner and 2 outer. The 2 inner primers are allele-specific
and result in allele-specific amplification. The inner
primer amplification depends on the genotype used in
the PCR. The 2 outer primers act as an internal control
and generate the outer fragment of the flanking locus of
the SNP. Unequal positioning of the inner primers from
the corresponding outer primer results in the generation
of PCR products with diverse sizes, which are then easily
identified in the gel [12].
In the current study, it was sought to investigate SNPs
in the 3′-UTR of the BRCA1 and explore their association
with BC in sporadic BC patients.
2. Materials and methods
2.1. Study subjects and ethical approval
This study included female patients (n = 300), ranging in
age from 22 to 68 years, with confirmed BC at the Institute

of Radiotherapy and Nuclear Medicine, in Peshawar,
Pakistan, and matching controls (n = 300), ranging in age
from 20 to 70 years, with no history of cancer, as shown
in Table 1.
Informed consent was given by all patients and healthy
controls included in the present study. The present study
followed the guidelines of the Helsinki declaration. The
current research work was approved by the Advanced
Study and Research Board at its 40th meeting held on
March 29, 2017, University of Malakand, Pakistan.
2.2. Inclusion/exclusion criteria and genomic DNA
extraction
The inclusion criterion for this study was a confirmed
history of BC, while women with no history of BC were
excluded. A total of 5 mL whole blood was collected
from the BC patients and healthy controls in EDTA tubes
and stored at refrigeration temperature until further
processing. Genomic DNA was isolated from the collected
blood samples using the phenol-chloroform method and it
was stored at –20 °C until further processing.
2.3. PCR-based amplification and Sanger sequencing of
BRCA1 gene
To amplify the 3′-UTRs of the BRCA1, 2 sets of primers
(Table 2) were used under the following thermocycling
conditions: initial denaturation at 95 °C for 10 min,
followed by 35 cycles of 95 °C for 1 min, primer annealing
at 56 °C for 30 s, extension at 72 °C for 1 min, and final
single step extension at 72 °C for 10 min. The PCR product

Table 1. Categorization of the preclinical data for each patient
with their age and cancer. stages (l–lV).
Age group

Stage 1 Stage II

Stage III

Stage IV Total

20s

3

9

3

6

21

30s

7

27

21

12

67

40s

7

34

22

16

79

50s

3

31

40

13

87

60s

5

8

19

5

37

70s

0

0

9

0

9

80s

0

0

0

0

0

109

114

52

300

Grand total 25

Table 2. List of primers used for amplification of the selected region of the BRCA1.
BRCA 1 primers

Primer sequences

BRCA1 3′-UTR 1 forward 5-AGCACTCTACCAGTGCCAG-3
BRCA1 3′-UTR 1 reverse

5-AGGTTTCAAGTTTCCTTTTCA-3

BRCA1 3′-UTR 2 forward 5-GAGTGCTTGGGATCGATTATGTGACTT-3
BRCA1 3′-UTR 2 reverse
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5-GCAACAGCTTCCTTCCTGGTGGG-3

Product size
646 bp
678 bp
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was visualized on 1% agarose gel by staining with ethidium
bromide.
The amplified region was commercially sequenced
using the Sanger sequencing method and the sequencing
results were compared with the reference sequence
obtained from the National Center for Biotechnology
Information (NCBI). The analysis was carried out using
Vector NTI software. Single nucleotide variants were
detected.
2.4. Allele-specific T-ARMS-PCR amplification
The SNP (rs8176318; G>T) in the 3′-UTRs of the BRAC1
was identified through Sanger sequencing. Further
screening was performed for genotyping of the selected
SNPs in the patients and controls using the T-ARMS PCR
technique. Primer 1 software, available online (http://
primer1.soton.ac.uk/primer1.html), was used to design
allele-specific primers for the identified SNPs (Table 3).
A PCR reaction mixture of 30 µL in a 0.2-mL PCR tube
containing approximately 100 ng/µL of DNA template,
17 µL of green-Taq PCR master mix (Thermo Fisher
Scientific Inc., Waltham, MA, USA), 4 µL of primers (1
µL of forward inner, 1 µL of inner reverse, 1 µL of forward
outer, and 1 µL of reverse outer primer) (each primer of
10 pmol/µL), and up to 7 µL of nuclease-free water was
prepared and processed. The amplification conditions used
were initial denaturation at 95 °C for 10 min, followed by
35 cycles of denaturation, annealing, and extension at 95
°C for 1 min, 56 °C for 40 s, and 72 °C for 40 s, respectively.
This was followed by the final extension step at 72 °C for
10 min. The products of amplification were separated by

subjection to electrophoresis on 3% Agarose gel. Ethidium
bromide was used for the staining and visualization of the
PCR products. The results were confirmed by reproducing
15% of the samples and the accuracy of reproducibility was
99%. Furthermore, the results of the Sanger sequencing
and T-ARMS PCR were 100% reproducible. The 3′-UTRs
of the BRCA1 were wild (GG) as well as mutant (TT)
genotypes, which yielded 177 bp, 279 bp products, while
the outer primer product was 400 bp, respectively, as
depicted in Figure 1.
2.5. Statistical analysis
The Hardy–Weinberg equilibrium was applied as quality
control to check the observed and expected genotype
frequencies in both the patients and controls. Codominant,
dominant, recessive, and additive models were applied on
the collected data. The odds ratio (OR) at 95% confidence
intervals (CIs) was also calculated. P < 0.05 was considered
significant.
3. Results
Through the alignment of the DNA sequences of the
BRCA1 against reference sequences from NCBI, using
gene sequencing analysis software, a genetic variant
(rs8176318; G>T) in the 3′UTRs of the BRCA1 was
identified. The variant was presented as homozygous (GG),
homozygous (TT), and heterozygous (GT) in the analyzed
samples (Figure 1). Furthermore, genotype data obtained
through the T-ARMS PCR were statistically analyzed
for association with BC (Table 4). Selected samples were
sequenced to confirm the result of the T-ARMS PCR. The

Table 3. List of the outer and inner primers used for the genotyping of (rs8176318) in the miRNAbinding site of the BRCA1.
Primer

Sequence

Product size

Forward inner primer (G allele) TTACTTCTCTAAAACCCTGTGTTCACAGAG

177 bp

Reverse inner primer (T allele)

TCCATTGAAGGGTCTGACTCTCTACA

279 bp

Forward outer primer (5′ - 3′)

CTTAAAGATTTTCTGCTTGAAGTCTCCCT

Reverse outer primer (5′ - 3′)

TTCCTTTTCATTTCTAATACCTGCCTCA

400 bp

Figure 1. Gel electrophoresis image of the T-ARMS-PCR for the detection of polymorphisms in the BRCA1. Genotypes are indicated
(lanes 1 and 8: GT; lane 3: TT; lanes 2, 4, 5, 6, 7: GG genotypes and M: marker).
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results obtained by the T-ARMS PCR were concordant
with the sequencing (Figure 2). The distribution of
genotypes was found to be consistent with the Hardy–
Weinberg equilibrium in both the BC patients (P = 0.5707)
and the controls (P = 0.4672). In the codominant model
(genotype frequency distribution), frequency of the GG
genotype was 31.33% (n = 94) in the BC patients and

22.67% (n = 68) in the controls. Similarly, frequency of
the GT genotype was higher in the BC patients (52.0%,
n = 156) than in the controls (47.67%, n = 143), whereas
the frequency of the TT genotype was significantly lower
in the BC patients (16.67%, n = 50) than in the controls
(29.67%, n = 89). Thus, a significant statistical difference
in the genotypes was determined through the codominant

Table 4. Genotype and allele frequencies between the subject and control groups at locus rs8176318) in
the miRNA-binding site of the BRCA1 using the codominant, dominant, recessive, and additive statistical
models.
Statistical models Genotypes
Co
dominant
Dominant
Recessive
Additive

GG
GT
TT
GG
TT + GT
TT
GG + GT
G
T

Patients (age%) Controls (age%)
94 (31.33)
156 (52.0)
50 (16.67)
94 (31.33)
206 (68.67)
50 (16.67)
250 (83.33)
344 (57.33)
256 (42.67)

68 (22.67)
143 (47.67)
89 (29.67)
68 (22.67)
232 (77.33)
89 (29.67)
211 (70.33)
279 (45.51)
334 (54.49)

Fisher’s exact test χ2 -value,
P-value
OR (95% Cl)
df
1.557
(1.082–2.241)
0.4742
(0.3204–0.7017)
1.609
(1.282–2.018)

15.68,
2

<0.0004

_

<0.0213

_

<0.0002

_

<0.0001

Figure 2. Validation assay to confirm the T-ARMS-PCR result using sequencing. The sequencing result of rs8176318 showed homozygote
(GG), heterozygous, and (CG) genotypes using reverse primer, respectively.
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model analysis (χ 2= 15.68; P < 0.004), indicating the role
of this variant in the risk of BC.
However, through the additive model (allele frequency
distribution) analysis, it was found that the G allele was
significantly higher in BC patients (57.33%) than in the
controls (45.51%). Thus, a significant difference in the allele
frequency was determined through the additive model
analysis in BC patients when compared to the controls,
with the following 95% CI: OR = 1.609 (1.282–2.018);
P < 0.0001, indicating that the G allele was a susceptible
allele, while the T allele was protective. Similarly, both the
dominant (GG vs. GT + TT) and recessive (TT vs. GT +
GG) statistical models showed a significant association
with the risk of BC, with a 95% CI of P < 0.0213 and P
< 0.0002, respectively, indicating that individuals with the
GG genotype were at risk of BC, while those with the TT
genotype were protected from this risk.
4. Discussion
In the current study, the association of (rs8176318; G>T)
with the risk of BC in the 3′-UTRs of the BRCA1 SNPs was
investigated. The risk of BC was found to be significantly
increased in individuals that had the GG or GT genotype
when compared with those that had the TT genotype, in
a Pakistani population. The TT genotype was observed
to have decreased the risk of BC when compared to the
GG genotype. The GG genotype had an OR of 1.557 and
appeared to be the risk allele, while the TT allele had an
OR of 0.47 and was found to provide protection against
BC in the Pakistani population analyzed in the current
study. Previous studies supported the observations made
herein that variants within the miRNA binding sites of
tumor suppressors or oncogenes play a pivotal role in the
development of BC [13]. When comparing the frequencies
of the 3′-UTRs of the BRCA1 G>T heterozygosity in this
study group with those of other studies, it was found
that the GT heterozygosity was generally comparable
with Italy (TSI) at 50%; Chinese in Colorado (CHD) at
56%; Gujarati Indians in Houston, Texas (GIH) at 52%;
European ancestry in Utah at %45; and 50% in a Saudi
Arabian population [14]. Herein, the frequencies of the
GG (31.33%), GT (52.0%), and TT (16.67%) genotypes
in the patients were comparable to those of the GIH
(29.5%, 52.3%, and 18.2%, respectively). Our G (57.3%)
and T (42.6%) allele frequencies were comparable to
those of the GIH (55.7% and 44.3%) and CHD (56.5%
and 44.5%) [15]. Previously, a study of African-American
women reported that the rs3092995 in the 3′-UTRs of the
BRCA1 increased the risk of BC [16]. In support of our
findings, another study showed that the nrs8176318 GG
genotype had a significantly lower expression level (of
BRCA1 mRNA) than the GT and TT genotypes. Previous

studies have supported our observations that variants
within the miRNA binding sites of tumor suppressors
or oncogenes play a role in BC development [13]. Other
studies have reported that different alleles, rs12516 and
rs8176318, increased the risk of BC [17]. The rs8176318
G/T variant was linked with increased risk of BC in
studies across different populations worldwide [15]. The
rs8176318 has also been reported to be a risk factor in
African-American women, with an OR of 12.19 [18]. In
contrast to our findings, some studies on variants inside
the 3′-UTRs of the BRCA1 have failed to show association
with the risk of BC [19]. Similarly, in another contrasting
study, the rs8176318 (T) variant in the BRCA1 has been
shown to lower the gene expression and was associated
with advancing the BC stage. According to another study,
a 4-fold increase was observed in the shift to stage V
of the disease [8]. That study is carried out on an Irish
population, whereas the study herein was carried out on
Asian population. Their study reported an increased risk
of triple-negative BC patients. Our results reveal that the
newly identified TT allele may be a new genetic marker
for a decreased risk of sporadic BC. On the other hand,
women with the GG allele are at an increased risk of
BC. It has been shown that the mutant (T) allele reduces
the BRCA1 expression in response to a decrease in the
amount of estrogen when compared to the G allele, which
showed that estrogen treatment dysregulated the T-allele
expression, causing the down-regulation of the BRCA1
[8]. The results of our study presented a variation in the
noncoding region of the BRCA1 that can influence its
expression, increasing the risk of BC in Pakistani females.
Evidence supporting the notion that susceptibility to BC is
increased by variants inside the 3′-UTRs is on the rise [20].
The reason for the association of SNPs in the 3′-UTRs with
increased risk of BC may be due to the fact that miRNAs
bind to mRNA in the 3′-UTRs; thus, regulating the levels of
mRNA and its expression [21]. In support of our findings,
it was indicated by previous work that 3′-UTR variants act
as genetic markers of the risk of cancer [22]. The major
reason for discrepancies in our results with those of other
studies was the diverse ethnic group (study population).
It was concluded that females with the GG genotype
invariant (rs8176318; G>T) had a higher risk of developing
BC, and women with the TT genotype in the 3′-UTRs
of the BRCA1 had less chance of developing BC when
compared to those with the GG genotype.
Acknowledgment
The authors are extremely grateful to the Higher Education
Commission of Pakistan for providing financial support
under the Indigenous PhD scholarship Scheme to Mr.
Mushtaq Ahmad (Ref. No. 213-59624-2BM2-131).

1437

AHMAD et al. / Turk J Med Sci
References
1.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al.
Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185
countries. Cancer Journal for Clinicians 2018; 68 (6): 394-424.
doi: 10.3322/caac.21492

2.

Zhong R, Liu L, Zou L, Sheng W, Zhu B et al. Genetic variations
in the TGFβ signaling pathway, smoking and risk of colorectal
cancer in a Chinese population. Carcinogenesis 2012; 34 (4):
936-942. doi: 10.1093/carcin/bgs395

3.

Venkitaraman AR. Cancer susceptibility and the functions of
BRCA1 and BRCA2. Cell 2002; 108 (2): 171-182. doi: 10.1016/
S0092-8674(02)00615-3

4.

Brodie SG, Deng C-X. BRCA1-associated tumorigenesis: what
have we learned from knockout mice? Trends in Genetics 2001;
17 (10): S18-S22. doi: 10.1016/S0168-9525(01)02451-9

5.

Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions
of mRNAs. Genome Biology 2002; 3 (3): REVIEWS0004.doi:
10.1186/gb-2002-3-3-reviews0004

6.

Hervé C, Mickleburgh I, Hesketh J. Zipcodes and postage
stamps: mRNA localisation signals and their trans-acting
binding proteins. Briefings in Functional Genomics 2004; 3
(3): 240-256. doi: 10.1093/bfgp/3.3.240

7.

Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F et al.
Targeted resequencing of the microRNAome and 3′ UTRome
reveals functional germline DNA variants with altered
prevalence in epithelial ovarian cancer. Oncogene 2015; 34
(16): 2125. doi: 10.1038/onc.2014.117

8.

Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C et al.
A germline mutation in the BRCA1 3′UTR predicts stage IV
breast cancer. BMC cancer 2014; 14 (1): 421. doi: 10.1186/14712407-14-421

9.

Chen K, Song F, Calin GA, Wei Q, Hao X et al. Polymorphisms
in microRNA targets: a gold mine for molecular epidemiology.
Carcinogenesis 2008; 29 (7): 1306-13011. doi: 10.1093/carcin/
bgn116

10.

Gaudet M, Fara AG, Beritognolo I, Sabatti M. Allele-specific
PCR in SNP genotyping. Methods in Molecualr Biology 2009;
415-424. doi: 10.1007/978-1-60327-411-1_26

11.

Medrano RFV, de Oliveira CA. Guidelines for the tetra-primer
ARMS-PCR technique development. Molecular Biotechnology
2014; 56 (7): 599-608. doi: 10.1007/s12033-014-9734-4

12.

Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient
procedure for genotyping single nucleotide polymorphisms.
Nucleic Acids Research 2001; 29 (17): e88-e. doi: 10.1093/
nar/29.17.e88

1438

13.

Wei J, Shi J, Yuan Q, Zhang X, Yang M et al. A functional
BRCA1 coding sequence genetic variant contributes to risk of
esophageal squamous cell carcinoma. Carcinogenesis 2013; 34
(10): 2309-2313. doi: 10.1093/carcin/bgt213

14.

Mir R, Javid J, Al Balawi IA, Alkharsah KR, Hadi MA et al.
A germline mutation in the BRCA1 3′UTR variant predicts
susceptibility to breast cancer in a Saudi Arabian population.
Asian Pacific Journal of Cancer Prevention 2018; 19 (3): 859866. doi: 10.22034/APJCP.2018.19.3.859

15.

Yang F, Chen F, Xu J, Guan X. Identification and frequency
of the rs12516 and rs8176318 BRCA1 gene polymorphisms
among different populations. Oncology letters 2016; 11 (4):
2481-2486. doi: 10.3892/ol.2016.4252

16.

Newman B, Mu H, Butler LM, Millikan RC, Moorman PG
et al. Frequency of breast cancer attributable to BRCA1 in a
population-based series of American women. Journal of the
American Medical Association 1998; 279 (12): 915-921. doi:
10.1001/jama.279.12.915

17.

Pongsavee M, Yamkamon V, Dakeng S, O-charoenrat P, Smith
DR et al. The BRCA1 3′-UTR: 5711+ 421T/T_5711+ 1286T/T
genotype is a possible breast and ovarian cancer risk factor.
Genetic Testing and Molecular Biomarkers 2009; 13 (3): 307317.

18.

Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R et al.
Rare BRCA1 haplotypes including 3′UTR SNPs associated with
breast cancer risk. Cell Cycle 2011; 10 (1): 90-99. doi: 10.4161/
cc.10.1.14359

19.

Freedman ML, Penney KL, Stram DO, Riley S, McKeanCowdin R et al. A haplotype-based case-control study of
BRCA1 and sporadic breast cancer risk. Cancer Research 2005;
65 (16): 7516-22. doi: 10.1158/0008-5472.CAN-05-0132

20.

Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P et
al. Polymorphisms within micro-RNA-binding sites and risk
of sporadic colorectal cancer. Carcinogenesis 2008; 29 (3): 579584. doi: 10.1093/carcin/bgm304

21.

Chen K, Song F, Calin GA, Wei Q, Hao X et al. Polymorphisms
in microRNA targets: a gold mine for molecular epidemiology.
Carcinogenesis 2008; 29 (7): 1306-1311. doi: 10.1093/carcin/
bgn116

22.

Chin LJ, Ratner E, Leng S, Zhai R, Nallur S et al. A SNP in a let7 microRNA complementary site in the KRAS 3′ untranslated
region increases non-small cell lung cancer risk. Cancer
Research 2008; 68 (20): 8535-8540. doi: 10.1158/0008-5472.
CAN-08-2129

